Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Joshua, 27, was diagnosed with autism at two and a half. He was nonverbal and experienced severe anxiety, while getting a full night's sleep remained a struggle for years.

An experimental drug called L1-79, touted as ‘Ozempic Of Autism' has reportedly brought significant improvements in his condition, according to the Daily Mail, raising interest in its potential to address core features of autism spectrum disorder (ASD).

How Did The Drug L1-79 Help Joshua?

Developed by Yamo Pharmaceuticals, L1-79 is an oral drug designed to target core symptoms of autism.

Joshua’s psychiatrist of eight years, Dr. Eric Bartky, an autism specialist involved in the US FDA trial of L1-79, asked his parents Linda and Jim Turteltaub to consider trying the drug.

The decision involved uncertainty. Taking part in the trial required Joshua to stop all his other medications, and the potential side effects of the new treatment were not fully known. Despite these concerns, his parents decided in 2015 to give it a try.

“We just wanted something to address the issues, to try and get him better so that he can at least communicate with us,” Linda said.

According to the report, Joshua showed his first notable improvement within a week of beginning treatment.

Also read: Autism Care Begins Early: Why the First 1,000 Days Matter Most, Says AIIMS Expert

How Does L1-79 Work?

Yamo Pharmaceuticals describes L1-79 as a selective inhibitor of tyrosine hydroxylase, an enzyme involved in the production of dopamine and norepinephrine.

The drug is intended to lower the production of these chemical messengers in an effort to regulate pathways that may contribute to sensory overload and social withdrawal in people with autism.

Dr. Bartky said the drug differs from existing approaches because it aims to address core features of autism, including social interaction and communication.

“What makes L1-79 different is that L1-79 treats the core symptoms of autism, things like socialization and communications, things that go along with that like eye contact, reciprocal conversation, nonverbal communication, such as reading social nuance. These are things that are extremely important for a person's emotional growth and functioning in society.”

The response to treatment has varied among Dr. Bartky's patients, reflecting the wide range of symptoms associated with ASD.

What Is The Status Of L1-79 Clinical Trials?

Read More: Stem Cell Therapy For Autism: What India’s New Advisory Means For Patients

There is currently no single medication that treats all the core features of autism spectrum disorder. Several medications are prescribed to manage particular behavioral patterns and associated conditions.

L1-79 is being investigated as a potential treatment that could address autism's underlying neurological features. The Daily Mail reported that 116 patients had participated in L1-79's three clinical trials.

The drug has received Fast Track designation from the US Food and Drug Administration (FDA). This program is intended to facilitate the development and review of treatments for serious conditions that address unmet medical needs.

Although the designation does not shorten the clinical trial process, it can make a drug eligible for priority review. Under this pathway, the FDA aims to complete its review within six months, compared with the standard 10-month timeline.

Are There Any Safety Concerns?

Dr. Bartky also pointed to what he described as L1-79's safety profile.

Some existing medications can cause serious side effects, including dyskinesia, which involves involuntary movements that can sometimes be permanent; metabolic syndrome, a group of conditions associated with increased risks of heart disease, stroke and type 2 diabetes; and hypertension. Dr. Bartky said L1-79 had “not had one single serious side effect.”

Are you among those who ditch plastic straws in favor of paper ones? A new South Korean study suggests that switching to paper may not be as environmentally beneficial as it seems.

Commissioned by South Korea's Ministry of Climate, Energy and Environment, the study found that paper straws had 6.33 times the carcinogenic impact of conventional plastic straws. They also had 2.04 times the impact on environmental acidification, which can make soil and water more acidic and potentially harm plants, animals and ecosystems.

What Did The Study Find?

Researchers compared the environmental impacts of conventional plastic straws made from polypropylene (PP), paper straws, biodegradable plastic straws and non-biodegradable bio-based polyethylene (bio-PE) straws.

The assessment, conducted from May last year to April this year, examined four types of straws across 16 environmental impact categories.

Traditional plastic straws had a lower environmental footprint in 10 of the 16 categories, including climate change, air pollution and human toxicity. Paper straws performed worse in categories including carcinogenic impact and environmental acidification.

Meanwhile, bio-PE straws had the highest environmental impact in 10 categories, including ozone depletion, environmental acidification and smog formation.

The findings highlight how the environmental footprint of everyday products can vary depending on the materials used to make them and how they are manufactured and disposed of.

Also read: Can Panty Liners Pose A Cancer Risk? What Science Says

How Was The Environmental Impact Assessed?

Researchers assessed each type of straw across its entire life cycle, from raw material production and manufacturing to disposal.

The analysis assumed that nearly 74% of discarded straws would be incinerated, while the remaining 26% would end up in landfills, The Korean Herald reported.

The results showed that conventional plastic straws performed better than the alternatives in several environmental categories. However, this does not mean they are the most environmentally friendly option in every respect.

Why Are Paper Straws Difficult To Recycle?

Despite being promoted as recyclable alternatives to plastic, paper straws can be difficult to recycle in practice.

Their small size makes them harder for recycling facilities to separate, while coatings and adhesives used in their manufacture can complicate the recycling process.

Paper straws have become commonplace in bars and fast-food outlets as the hospitality industry has moved away from plastic amid consumer concerns about plastic pollution. Although paper generally breaks down more readily than conventional plastic, its overall environmental impact depends on several factors, including production and disposal.

Paper Straws May Contain More 'Forever Chemicals'

Read More: 485 'Inactive' Chemicals In US Pesticide Products Linked To Breast Cancer

A previous study by researchers at the University of Antwerp in Belgium found that paper straws contained per- and polyfluoroalkyl substances (PFAS), commonly known as forever chemicals, more frequently than plastic straws.

These chemicals can persist in the environment for decades, contaminate water supplies and are associated with several health concerns. However, detecting PFAS in a product does not, by itself, establish the level of exposure or the risk to human health from using it.

Trump Administration Moves To Phase Out Paper Straws

In March 2025, the Trump administration launched an effort to phase out paper straws in federal government operations, releasing a White House report titled National Strategy to End the Use of Paper Straws.

The report argued that paper straws were more expensive, less effective and potentially more harmful than conventional plastic alternatives.

President Donald Trump described paper straws as a “pulpy, soggy mess” and raised concerns about the presence of PFAS, chemicals associated with cancer and other health problems, The Daily Mail reported.

Avian influenza, or bird flu, is caused by Type A influenza viruses found naturally in wild birds. The virus can spread to poultry and mammals, including dairy cattle. Humans can become infected through contact with infected animals or contaminated environments. While sustained human-to-human transmission of H5N1 has not been established, continued outbreaks and the virus's potential to evolve are raising concerns about the risk of a future pandemic, experts warn.

Early this month, a resident of Yakima County in Washington tested positive for avian influenza after exposure to infected dairy cattle, the Yakima Health District and Washington State Department of Health announced. The resident is isolating at home and has not developed severe illness or required hospitalization.

H5N1 In Humans: What Do We Know?

According to the Pan American Health Organization (PAHO), 1,002 laboratory-confirmed human H5N1 infections and 479 deaths were reported across 25 countries between 2003 and August 7, 2026. In 2026 alone, nine cases, including two deaths, were reported worldwide.

The H5N1 clade 2.3.4.4b circulating among US dairy cattle has been less lethal to humans than some other H5N1 infections. The US has reported at least 72 human cases since the virus spread to dairy cattle, with two deaths. Most patients had contact with infected animals, The Telegraph reportedd.

Symptoms include fever, cough, sore throat, muscle aches and conjunctivitis. Mild infections may resemble COVID-19 or the common cold, potentially leaving cases undetected.

Migrant dairy workers may also avoid voluntary testing over fears of contact with law enforcement.

“If people don’t feel safe coming forward for testing or care, we risk missing early signs of spread, especially in high-risk populations like dairy farm workers,” Dr Krutika Kuppalli, associate professor in the division of infectious diseases at the University of Texas Southwestern, previously told The Telegraph.

H5N1 Detected In Mink On US Farm

H5N1 has been detected in at least six captive mink on a Utah farm, according to the US Department of Agriculture (USDA).

Scientists are monitoring the virus in mammals because some species can support viral replication and transmission. Mink are of particular concern because they are susceptible to respiratory viruses, and crowded farms could create conditions for viruses to spread and evolve.

"It is REALLY dangerous to let bird flu spread unchecked through mammals, especially minks, which have similar susceptibility & respiratory physiology to humans. The virus can adapt to human hosts by adapting to the respiratory tract of minks," virologist Dr Angela Rasmussen said, in a post on X.

"We don't know if H5N1 will ever make that evolutionary leap or not. We know that it could. But I hope we don't find out. A worst-case bird flu pandemic could literally kill hundreds of millions of people & cause agricultural, ecological, & economic collapse," she added.

How H5N1 Spread From Birds To Dairy Cattle

Marc Johnson, a molecular virologist and professor, shared a timeline of H5N1's spread on X. A new variant spread across the US in early 2022, causing substantial bird mortality and spilling over into several mammal species.

In late 2023 or early 2024, the virus began appearing in dairy cattle's mammary tissue. By the time the outbreak was identified, it had spread to herds across the country.

Johnson said bulk milk testing and strict quarantines could have helped contain the outbreak, warning that the virus continues to circulate among cattle.

"Pasteurization kills H5N1," he said, adding no human cases have been linked to drinking pasteurized milk.

Could H5N1 Trigger Another Pandemic?

Scientists are concerned that continued circulation in mammals could allow H5N1 to evolve and become better adapted to mammalian hosts, potentially increasing the risk to humans.

Johnson warned that "continued spread gives the virus more opportunities to evolve". While sustained human-to-human transmission has not been established, a future pandemic remains inevitable.

How Can You Reduce Your Risk?

People who work closely with animals, including agricultural workers, backyard flock owners, hunters and wildlife workers, face a higher risk.

• Avoid touching sick or dead animals, wild birds, bird droppings and potentially contaminated surfaces.
• Use appropriate personal protective equipment (PPE) when handling infected animals and report suspected animal infections.
• Wear disposable gloves when handling harvested birds and practice good hygiene.
• Ask a healthcare provider about seasonal flu vaccination. It does not prevent bird flu but may reduce the risk of simultaneous infection with human and avian influenza viruses.